相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI
Kevin W. Moore et al.
JOURNAL OF IMMUNOLOGY (2012)
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Cyril Fauriat et al.
BLOOD (2010)
Association of an NKG2D gene variant with systemic lupus erythematosus in two populations
Gamze Kabalak et al.
HUMAN IMMUNOLOGY (2010)
NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies
J. Luis Espinoza et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Interferon-γ down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells
Nicole Schwinn et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
Tadepally Lakshmikanth et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Cutting Edge: Down-Regulation of MHC Class I-Related Chain A on Tumor Cells by IFN-gamma-Induced MicroRNA
Deepak Yadav et al.
JOURNAL OF IMMUNOLOGY (2009)
Brief Residence at the Plasma Membrane of the MHC Class I-Related Chain B Is Due to Clathrin-Mediated Cholesterol-Dependent Endocytosis and Shedding
Sonia Agueera-Gonzalez et al.
JOURNAL OF IMMUNOLOGY (2009)
Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells
Paolo Carrega et al.
PLOS ONE (2009)
Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors
Mar Vales-Gomez et al.
CANCER RESEARCH (2008)
Tumor-associated MICA is shed by ADAM proteases
Inja Waldhauer et al.
CANCER RESEARCH (2008)
Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors
Cai Zhang et al.
CANCER SCIENCE (2008)
Tumor cell recognition by the NK cell activating receptor NKG2D
Yenan T. Bryceson et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Nadia Guerra et al.
IMMUNITY (2008)
Intracellular retention of the NKG2D ligand MHC class I chain-related gene a in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity
Mercedes B. Fuertes et al.
JOURNAL OF IMMUNOLOGY (2008)
Regulation of NKG2D ligands: a purposeful but delicate affair
Thomas Spies
NATURE IMMUNOLOGY (2008)
Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D
Noam Stern-Ginossar et al.
NATURE IMMUNOLOGY (2008)
Up on the tightrope: natural killer cell activation and inhibition
Lewis L. Lanier
NATURE IMMUNOLOGY (2008)
NKG2D ligands in tumor immunity
N. Nausch et al.
ONCOGENE (2008)
Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance
Arun M. Unni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
NKG2D-Mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients
Cristina Maccalli et al.
CLINICAL CANCER RESEARCH (2007)
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
Yasser M. El-Sherbiny et al.
CANCER RESEARCH (2007)
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands
Brett K. Kaiser et al.
NATURE (2007)
Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B Ligands of NKG2D
Gopalakrishnan M. Venkataraman et al.
JOURNAL OF IMMUNOLOGY (2007)
TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells
Guenter Eisele et al.
BRAIN (2006)
Human NK cell education by inhibitory receptors for MHC class I
Nicolas Anfossi et al.
IMMUNITY (2006)
Proteolytic release of soluble UL16-binding protein 2 from tumor cells
I Waldhauer et al.
CANCER RESEARCH (2006)
Regulation of NKG2D ligand gene expression
Robert A. Eagle et al.
HUMAN IMMUNOLOGY (2006)
NKG2D and cytotoxic effector function in tumor immune surveillance
Yoshihiro Hayakawa et al.
SEMINARS IN IMMUNOLOGY (2006)
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B
S Skov et al.
CANCER RESEARCH (2005)
Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells
YT Bryceson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance
DE Oppenheim et al.
NATURE IMMUNOLOGY (2005)
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo
K Wiemann et al.
JOURNAL OF IMMUNOLOGY (2005)
Targeting STAT3 affects melanoma on multiple fronts
M Kortylewski et al.
CANCER AND METASTASIS REVIEWS (2005)
Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells
JD Coudert et al.
BLOOD (2005)
Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis
TX Xie et al.
ONCOGENE (2004)
Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells
P Wolint et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors
P André et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma
L Raffaghello et al.
NEOPLASIA (2004)
A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells
M Kurte et al.
JOURNAL OF IMMUNOLOGY (2004)
Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients
JC Lee et al.
JOURNAL OF IMMUNOLOGY (2004)
CD107a as a functional marker for the identification of natural killer cell activity
G Alter et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma
CS Vetter et al.
BRITISH JOURNAL OF CANCER (2004)
RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo
MA Friese et al.
CANCER RESEARCH (2004)
The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases
E Weiss et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Axis of evil: molecular mechanisms of cancer metastasis
T Bogenrieder et al.
ONCOGENE (2003)
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells
V Rubio et al.
NATURE MEDICINE (2003)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding
HR Salih et al.
JOURNAL OF IMMUNOLOGY (2002)
A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3
M Radosavljevic et al.
GENOMICS (2002)
ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
D Cosman et al.
IMMUNITY (2001)
分享论文
